STAAR Surgical (NASDAQ:STAA) Issues Earnings Results, Beats Estimates By $0.17 EPS

STAAR Surgical (NASDAQ:STAA) posted its earnings results on Wednesday. The medical instruments supplier reported $0.39 EPS for the quarter, beating the consensus estimate of $0.22 by $0.17, reports. STAAR Surgical had a return on equity of 9.05% and a net margin of 1.13%.The firm had revenue of $93.54 million for the quarter, compared to analysts’ expectations of $90.60 million. During the same period last year, the firm earned ($0.34) EPS. The firm’s revenue was up 111.1% compared to the same quarter last year.

Here are the key takeaways from STAAR Surgical’s conference call:

• Record first-half performance: Second-quarter revenue rose 111% year over year to $93.5 million, supported by sequential growth in China and double-digit growth across the Americas and EMEA excluding the Middle East.
• Profitability and cash flow improved materially. Net income reached $8.1 million versus a $16.8 million loss a year earlier, adjusted EBITDA was $20 million, and cash increased to $181.5 million with no debt; management expects to end 2026 with more than $200 million in cash.
• EVO+ is gaining traction in China and driving market-share gains. China revenue grew 10% sequentially to $52.3 million, EVO+ represented nearly one-third of units exiting the quarter, and the product commanded a premium without apparent customer resistance, although supply remains constrained.
• Near-term comparisons and operating headwinds remain significant. Third-quarter 2025 included a nonrecurring $25.9 million order, China is expected to be seasonally lower than the second quarter, and tariffs on U.S.-manufactured products will pressure margins until shipments to China are fully produced in Switzerland, targeted by the end of 2026.
• STAAR is broadening its innovation strategy beyond EVO. The company is preparing for first-in-human studies of next-generation products and plans to hire a chief technology officer to develop a broader, Collamer-centered ophthalmology platform.

STAAR Surgical Stock Up 2.2%

Shares of STAA traded up $0.52 during mid-day trading on Tuesday, reaching $24.61. The company’s stock had a trading volume of 350,103 shares, compared to its average volume of 1,188,651. The company has a market cap of $1.23 billion, a price-to-earnings ratio of 351.35 and a beta of 1.26. The business has a fifty day moving average of $26.69 and a 200 day moving average of $24.21. STAAR Surgical has a 1 year low of $15.59 and a 1 year high of $35.87.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in STAA. Invesco Ltd. boosted its position in STAAR Surgical by 7.1% during the fourth quarter. Invesco Ltd. now owns 161,548 shares of the medical instruments supplier’s stock valued at $3,730,000 after purchasing an additional 10,652 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of STAAR Surgical during the 4th quarter worth about $746,000. Symmetry Investments LP acquired a new stake in shares of STAAR Surgical during the 4th quarter valued at about $924,000. Millennium Management LLC grew its stake in shares of STAAR Surgical by 125.4% in the 4th quarter. Millennium Management LLC now owns 451,291 shares of the medical instruments supplier’s stock valued at $10,420,000 after buying an additional 251,072 shares in the last quarter. Finally, AQR Arbitrage LLC increased its holdings in STAAR Surgical by 45.1% in the fourth quarter. AQR Arbitrage LLC now owns 914,573 shares of the medical instruments supplier’s stock worth $21,117,000 after buying an additional 284,073 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on STAA shares. Canaccord Genuity Group boosted their price objective on STAAR Surgical from $27.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Wedbush dropped their price target on shares of STAAR Surgical from $40.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Zacks Research raised shares of STAAR Surgical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Weiss Ratings raised shares of STAAR Surgical from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Thursday. Finally, Wells Fargo & Company boosted their target price on shares of STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.40.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.